GB201205669D0 - Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof - Google Patents

Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof

Info

Publication number
GB201205669D0
GB201205669D0 GBGB1205669.3A GB201205669A GB201205669D0 GB 201205669 D0 GB201205669 D0 GB 201205669D0 GB 201205669 A GB201205669 A GB 201205669A GB 201205669 D0 GB201205669 D0 GB 201205669D0
Authority
GB
United Kingdom
Prior art keywords
mnk2
compounds
diseases
modulators
bicyclic heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1205669.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Priority to GBGB1205669.3A priority Critical patent/GB201205669D0/en
Publication of GB201205669D0 publication Critical patent/GB201205669D0/en
Priority to SG11201406207PA priority patent/SG11201406207PA/en
Priority to PL13768800T priority patent/PL2831079T3/pl
Priority to AU2013240612A priority patent/AU2013240612B2/en
Priority to DK13768800.8T priority patent/DK2831079T3/da
Priority to CN201380027654.7A priority patent/CN104350055B/zh
Priority to JP2015503165A priority patent/JP6475158B2/ja
Priority to SG10201706594PA priority patent/SG10201706594PA/en
Priority to NO13768800A priority patent/NO2831079T3/no
Priority to PL17179630.3T priority patent/PL3321268T3/pl
Priority to ES17179630T priority patent/ES3034431T3/es
Priority to KR1020147027686A priority patent/KR102153320B1/ko
Priority to BR112014024255-0A priority patent/BR112014024255B1/pt
Priority to ES13768800.8T priority patent/ES2647959T3/es
Priority to EP17179630.3A priority patent/EP3321268B1/en
Priority to PCT/SG2013/000126 priority patent/WO2013147711A1/en
Priority to US14/363,718 priority patent/US9908886B2/en
Priority to EP13768800.8A priority patent/EP2831079B1/en
Priority to US14/517,415 priority patent/US10280168B2/en
Priority to AU2017219039A priority patent/AU2017219039A1/en
Priority to US15/872,571 priority patent/US20180208600A1/en
Priority to JP2018206109A priority patent/JP6662984B2/ja
Priority to US16/298,959 priority patent/US20190211020A1/en
Priority to US16/432,469 priority patent/US11040978B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1205669.3A 2012-03-30 2012-03-30 Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof Ceased GB201205669D0 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
GBGB1205669.3A GB201205669D0 (en) 2012-03-30 2012-03-30 Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
EP13768800.8A EP2831079B1 (en) 2012-03-30 2013-04-01 Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof
ES17179630T ES3034431T3 (en) 2012-03-30 2013-04-01 Bicyclic heteroaryl derivatives as mnk1 and mnk2 modulators and uses thereof
BR112014024255-0A BR112014024255B1 (pt) 2012-03-30 2013-04-01 Derivados de heteroarila bicíclica como moduladores de mnk1 e mnk2 e a utilização dos mesmos
AU2013240612A AU2013240612B2 (en) 2012-03-30 2013-04-01 Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof
DK13768800.8T DK2831079T3 (da) 2012-03-30 2013-04-01 BICYKLISKE HETEROCYKLISKE DERIVATER SOM MNK1- og MNK2-MODULATORER OG ANVENDELSER DERAF
CN201380027654.7A CN104350055B (zh) 2012-03-30 2013-04-01 作为mnk1和mnk2调节剂的二环杂芳基衍生物及其用途
JP2015503165A JP6475158B2 (ja) 2012-03-30 2013-04-01 Ｍｎｋ１およびｍｎｋ２調節剤としての二環式ヘテロアリール誘導体、およびその使用
SG10201706594PA SG10201706594PA (en) 2012-03-30 2013-04-01 Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof
NO13768800A NO2831079T3 (enExample) 2012-03-30 2013-04-01
PL17179630.3T PL3321268T3 (pl) 2012-03-30 2013-04-01 Bicykliczne pochodne heteroarylowe jako modulatory mnk1 oraz mnk2 i ich zastosowania
SG11201406207PA SG11201406207PA (en) 2012-03-30 2013-04-01 Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof
KR1020147027686A KR102153320B1 (ko) 2012-03-30 2013-04-01 Mnk1 및 mnk2 조절제로서 바이시클릭 헤테로시클릭 및 이의 용도
PL13768800T PL2831079T3 (pl) 2012-03-30 2013-04-01 Dwucykliczne heterocykliczne pochodne jako modulatory mnk1 i mnk2 oraz ich zastosowanie
ES13768800.8T ES2647959T3 (es) 2012-03-30 2013-04-01 Derivados heterocíclicos bicíclicos como moduladores de MNK1 y MNK2 y usos de los mismos
EP17179630.3A EP3321268B1 (en) 2012-03-30 2013-04-01 Bicyclic heteroaryl derivatives as mnk1 and mnk2 modulators and uses thereof
PCT/SG2013/000126 WO2013147711A1 (en) 2012-03-30 2013-04-01 Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof
US14/363,718 US9908886B2 (en) 2012-03-30 2013-04-01 Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof
US14/517,415 US10280168B2 (en) 2012-03-30 2014-10-17 Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
AU2017219039A AU2017219039A1 (en) 2012-03-30 2017-08-24 Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
US15/872,571 US20180208600A1 (en) 2012-03-30 2018-01-16 Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof
JP2018206109A JP6662984B2 (ja) 2012-03-30 2018-10-31 Ｍｎｋ１およびｍｎｋ２調節剤としての二環式ヘテロアリール誘導体、およびその使用
US16/298,959 US20190211020A1 (en) 2012-03-30 2019-03-11 Bicyclic heteroaryl derivatives as mnk1 and mnk2 modulators and uses thereof
US16/432,469 US11040978B2 (en) 2012-03-30 2019-06-05 Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1205669.3A GB201205669D0 (en) 2012-03-30 2012-03-30 Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof

Publications (1)

Publication Number Publication Date
GB201205669D0 true GB201205669D0 (en) 2012-05-16

Family

ID=46160013

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1205669.3A Ceased GB201205669D0 (en) 2012-03-30 2012-03-30 Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof

Country Status (14)

Country Link
US (3) US9908886B2 (enExample)
EP (2) EP2831079B1 (enExample)
JP (2) JP6475158B2 (enExample)
KR (1) KR102153320B1 (enExample)
CN (1) CN104350055B (enExample)
AU (2) AU2013240612B2 (enExample)
BR (1) BR112014024255B1 (enExample)
DK (1) DK2831079T3 (enExample)
ES (2) ES3034431T3 (enExample)
GB (1) GB201205669D0 (enExample)
NO (1) NO2831079T3 (enExample)
PL (2) PL2831079T3 (enExample)
SG (2) SG11201406207PA (enExample)
WO (1) WO2013147711A1 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2868302A1 (en) 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
US9573953B2 (en) 2013-02-21 2017-02-21 Calitor Sciences, Llc Heteroaromatic compounds as PI3 kinase modulators and methods of use
WO2014151630A2 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
WO2014151729A1 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
GB2518873A (en) * 2013-10-03 2015-04-08 Agency Science Tech & Res Bicyclic alkyne derivatives and uses thereof
ES2809535T3 (es) * 2013-12-09 2021-03-04 UCB Biopharma SRL Derivados de imidazopiridina como moduladores de la actividad de TNF
PL3083627T3 (pl) 2013-12-19 2019-02-28 Novartis Ag Pochodne [l,2,4]triazolo[l,5-a]pyrimidyny jako inhibitory proteasomu pierwotniaka do leczenia chorób pasożytnych, takich jak leiszmanioza
RU2016132574A (ru) * 2014-01-09 2018-02-12 Интра-Селлулар Терапиз, Инк. Органические соединения
SG10202000191YA (en) 2014-01-24 2020-03-30 Turning Point Therapeutics Inc Diaryl macrocycles as modulators of protein kinases
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
NZ723203A (en) 2014-02-13 2020-08-28 Incyte Corp Cyclopropylamines as lsd1 inhibitors
PH12020552066A1 (en) 2014-02-13 2022-05-11 Incyte Corp Cyclopropylamines as lsd1 inhibitors
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
KR102891799B1 (ko) 2015-04-20 2025-11-26 이펙터 테라퓨틱스, 인크. 암 및 감염 치료에 사용하기 위한 면역 체크포인트 조절 인자의 억제제
DK3288940T5 (da) * 2015-04-29 2021-09-20 Janssen Pharmaceutica Nv Azabenzimidazoler og deres anvendelse som ampa-receptormodulatorer
EA201890086A1 (ru) 2015-06-18 2018-06-29 Сефалон, Инк. 1,4-замещенные производные пиперидина
ES2849951T3 (es) 2015-06-18 2021-08-24 89Bio Ltd Derivados de piperidina 4-bencil y 4-benzoil sustituidos
JP6871903B2 (ja) 2015-07-02 2021-05-19 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
RU2765181C2 (ru) 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
LT3733187T (lt) 2015-07-21 2024-12-10 Turning Point Therapeutics, Inc. Chiralinis diarilo makrociklas ir jo panaudojimas vėžio gydymui
LT3334709T (lt) 2015-08-12 2025-03-10 Incyte Holdings Corporation Lsd1 inhibitoriaus druskos
US10730842B2 (en) 2015-09-03 2020-08-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
CN108349956A (zh) * 2015-10-22 2018-07-31 赛尔维他股份公司 吡啶酮衍生物及其作为激酶抑制剂的用途
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
BR112018008711A2 (pt) 2015-10-29 2018-10-30 Effector Therapeutics Inc compostos de pirrolo-, pirazolo-, imidazo-pirimidina e piridina que inibem mnk1 e mnk2
EA201891049A1 (ru) 2015-10-29 2018-10-31 Эффектор Терапьютикс, Инк. Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2
US10000487B2 (en) 2015-11-20 2018-06-19 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
WO2017117052A1 (en) 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
MX387322B (es) 2016-04-22 2025-03-18 Incyte Corp Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
SG11201900163PA (en) 2016-07-28 2019-02-27 Tp Therapeutics Inc Macrocycle kinase inhibitors
GB201700692D0 (en) * 2017-01-16 2017-03-01 Salvensis Novel compounds and their use in the treatment of schistosomiasis
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
DK3582776T3 (da) 2017-02-14 2024-01-08 Effector Therapeutics Inc Piperidinsubstituerede mnk-hæmmere og dertil relaterede fremgangsmåder
SMT202400343T1 (it) 2017-07-28 2024-11-15 Turning Point Therapeutics Inc Composti macrociclici e loro usi
HUE060711T2 (hu) 2017-12-19 2023-04-28 Turning Point Therapeutics Inc Makrociklusos vegyületek betegségek kezelésére
AU2019222026B2 (en) * 2018-02-13 2022-05-12 Shanghai Blueray Biopharma Co., Ltd. Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
CN115448923B (zh) * 2018-02-13 2024-03-22 上海青煜医药科技有限公司 嘧啶并环化合物及其制备方法和应用
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2020069418A1 (en) * 2018-09-28 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk1/clk and uses thereof
KR20210102211A (ko) 2018-10-24 2021-08-19 이펙터 테라퓨틱스, 인크. Mnk 억제제의 결정질 형태
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
CN111978317A (zh) * 2019-05-22 2020-11-24 上海道熵生物科技有限公司 咪唑并吡啶类mnk1/mnk2激酶抑制剂及其制备方法和应用
CN111978325B (zh) * 2019-05-22 2023-11-17 中国药科大学 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用
TWI759829B (zh) 2019-08-23 2022-04-01 財團法人生物技術開發中心 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
JP7345220B2 (ja) * 2019-08-30 2023-09-15 ティーエスディー ライフ サイエンス カンパニー リミテッド イミダゾピリジン誘導体及びこれを有効成分として含有する薬学的組成物
CN115038471B (zh) * 2019-12-30 2024-05-14 德维护理有限公司 用于与植入泌尿道的装置相关的临床并发症的组合物
CN112047950B (zh) * 2020-09-14 2023-07-25 华东师范大学 咪唑并吡嗪类衍生物及其合成方法和应用
US20230355617A1 (en) * 2020-09-14 2023-11-09 The University Of Sussex Small molecule inhibitors of lemur tyrosine kinase 3
US20230000986A1 (en) * 2021-07-01 2023-01-05 Board Of Regents, The University Of Texas System Mnk inhibitors and eif4e phosphorylation modulation to treat inflammatory pain in the aged
US20250042920A1 (en) * 2021-11-29 2025-02-06 Ocean University Of China Imidazothiazole derivative, preparation method therefor, and application thereof
CN114113639B (zh) * 2022-01-29 2022-04-19 北京大有天弘科技有限公司 一种血型抗体检测方法及其应用
CN118908959B (zh) * 2023-05-08 2025-11-14 广西大学 咪唑并[1,2-b]哒嗪类化合物及其制备方法和PI3K抑制剂应用
ES2993583B2 (es) * 2023-06-27 2025-09-22 Univ Valencia Derivados de imidazo[1,2-a]piridina con actividad antiinflamatoria
WO2025165301A1 (en) * 2024-01-31 2025-08-07 National University Of Singapore Targeting metabolic pathways with mnk inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1746099A1 (en) * 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
JP2009502734A (ja) * 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
EP1991547A2 (en) * 2006-03-09 2008-11-19 Pharmacopeia, Inc. 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
ATE456565T1 (de) * 2006-06-22 2010-02-15 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
WO2008058126A2 (en) * 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
US20120058997A1 (en) * 2006-11-06 2012-03-08 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
CA2672172C (en) * 2006-12-22 2016-05-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
AR067326A1 (es) * 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
CA2703037A1 (en) * 2007-10-17 2009-04-23 Novartis Ag Organic compounds
WO2010055072A2 (en) * 2008-11-12 2010-05-20 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating a mnk
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
DK2467141T3 (en) * 2009-08-17 2019-02-18 Intellikine Llc HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
CN102770414A (zh) * 2010-04-28 2012-11-07 第一三共株式会社 ［5,6］杂环化合物
CA2806655A1 (en) * 2010-07-28 2012-02-02 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-b]pyridazines
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
JP2016510764A (ja) * 2013-03-07 2016-04-11 カリフィア バイオ, インク.Califia Bio, Inc. 混合系キナーゼ阻害剤および治療法

Also Published As

Publication number Publication date
AU2013240612A1 (en) 2014-10-16
BR112014024255B1 (pt) 2021-12-28
KR20150002639A (ko) 2015-01-07
JP6475158B2 (ja) 2019-02-27
KR102153320B1 (ko) 2020-09-08
SG11201406207PA (en) 2014-11-27
US9908886B2 (en) 2018-03-06
NO2831079T3 (enExample) 2018-01-13
EP2831079A1 (en) 2015-02-04
ES3034431T3 (en) 2025-08-18
CN104350055A (zh) 2015-02-11
JP6662984B2 (ja) 2020-03-11
JP2019031560A (ja) 2019-02-28
SG10201706594PA (en) 2017-09-28
BR112014024255A2 (pt) 2017-06-20
DK2831079T3 (da) 2017-11-27
EP3321268C0 (en) 2025-06-04
US20180208600A1 (en) 2018-07-26
WO2013147711A1 (en) 2013-10-03
CN104350055B (zh) 2019-05-31
EP2831079B1 (en) 2017-08-16
PL2831079T3 (pl) 2018-01-31
EP3321268B1 (en) 2025-06-04
PL3321268T3 (pl) 2025-11-17
AU2017219039A1 (en) 2017-09-14
AU2013240612B2 (en) 2017-05-25
US20190315755A1 (en) 2019-10-17
ES2647959T3 (es) 2017-12-27
US20140371199A1 (en) 2014-12-18
EP2831079A4 (en) 2015-11-18
JP2015511638A (ja) 2015-04-20
US11040978B2 (en) 2021-06-22
EP3321268A1 (en) 2018-05-16

Similar Documents

Publication Publication Date Title
GB201205669D0 (en) Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
GB201104267D0 (en) Pyrrolopyridineamino derivatives
NZ630925A (en) Pyrazolopyrimidine compounds as kinase inhibitors
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
MX2020011079A (es) Forma cristalina de sulfato acido de (s)-n-(5-((r)-2-(2,5-difluoro fenil)-pirrolidin-1-il)-pirazolo[1,5-a]-pirimidin-3-il)-3-hidroxi pirrolidina-1-carboxamida.
EP4233869A3 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX2015010858A (es) Formas solidas de un inhbidor de cdk4/6 selectivo.
CU20140065A7 (es) DERIVADOS DE 5-(1-BENZOTIOFEN-2-IL) PIRROLO[2,1-f][1,2,4]TRIAZIN-4-AMINA
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
PH12013500299B1 (en) Pyrrolopyrimidine compounds and uses thereof
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
MX368112B (es) Pirrolo- o pirazolopirimidinas covalentes reversibles utiles para el tratamiento del cancer y de enfermedades autoinmunitarias.
MX2013012981A (es) Compuestos de indazol sustituidos como inhibidores de las cinasas de proteina.
MX347040B (es) Inhibidores de tirosina-cinasas.
NZ630457A (en) Compounds useful as inhibitors of atr kinase
MX2011012037A (es) Compuestos de heteroarilo como inhibidores de pikk.
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
IN2014MN00987A (enExample)
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
HK1213888A1 (zh) 治療化合物和組合物以及其作為pkm2調節劑的用途
WO2014070991A3 (en) Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
GB201302704D0 (en) Therapeutic compounds
MX2014000964A (es) Derivados aza heterociclicos sustituidos.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)